文献速递放疗物理与技术

外照射放疗成本分析的质量评估:数据可靠性如何?

Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?
PubMed 文献 · Radiother Oncol · 2019-10-17

结果显示方法学质量尚可(CHEC 69.7%,QHES 73.6%),但报告透明度不足(CHEERS 59.4%),时间范围、贴现率和敏感性分析等关键条目常不完整。

要点

  • 外照射放疗成本分析的方法学质量尚可,但报告透明度不足。
  • 时间范围、贴现率和敏感性分析等关键成本方法学条目常仅部分完成。
  • 成本计算对最终卫生经济评价结果的影响可能被低估。

核心结论

  • 外照射放疗成本分析的定性定量评估显示方法学和报告透明度处于尚可水平。
  • 成本计算对最终卫生经济评价结果的影响似乎被低估。
  • 需要提高数据来源和方法学的透明度。

研究设计与样本

  • 使用CHEC、QHES和CHEERS三种验证工具评估方法学与报告质量,并进行定量与定性分析。
  • 采用Kendall一致性系数和组内相关系数检验评分稳健性。

主要发现

  • 成本分析主要地理区域为加拿大(n=5)、法国(n=4)和美国(n=4)。
  • 最常见研究的病理为前列腺癌(n=7)和头颈癌(n=5),技术为IMRT(n=8)和IGRT(n=2)。
  • 第一时段平均工具得分:CHEC 69.7%,QHES 73.6%,CHEERS 59.4%。
  • 第二时段平均工具得分:CHEC 74.4%,QHES 71.5%,CHEERS 66.1%。
  • 定性分析显示时间范围、贴现率、敏感性分析等条目常仅部分完成。

关键数值与推荐

  • CHEC评分第一时段69.7%,第二时段74.4%。
  • QHES评分第一时段73.6%,第二时段71.5%。
  • CHEERS评分第一时段59.4%,第二时段66.1%。

临床怎么用

  • 解读放疗成本分析时需关注方法学质量和报告透明度。
  • 应重视时间范围、贴现率和敏感性分析等关键成本方法学条目的完整性。
  • 卫生经济评价结果需结合数据来源和方法学透明度谨慎应用。

局限性

  • 三种工具评分虽一致但排名存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Health economic evaluations (HEE) are increasingly having an impact on policymakers, although the results greatly depend on the quality of the methodology used and on transparent reporting. The two main objectives of this study were to evaluate the quality of cost analyses of external beam radiotherapy (EBRT) and to assess the comprehensiveness and relevance of cost criteria defined in three validated quality-assessment instruments. MATERIALS AND METHODS: The selection of articles was based on a previous systematic literature review of EBRT-costing studies retrieved from January 2004 to January 2015 (Period 1) in MEDLINE, Embase, and NHS-EED databases and completed in a second time period from January 2015 to November 2018 (Period 2). Three validated instruments to assess the methodology quality with the CHEC and the QHES, and the methodology with the CHEERS checklists were used. The quality was evaluated by both quantitative and qualitative analyses. The scoring robustness was examined with the Kendall coefficient of concordance and inter-class correlation coefficients. RESULTS: In total, twenty-three articles were selected. The main geographic areas of cost analyses were Canada (n = 5), France (n = 4), and the USA (n = 4). The most commonly studied pathologies and technologies were prostate (n = 7) and head and neck cancer (n = 5) and IMRT (n = 8) and IGRT (n = 2), respectively. The mean instrument scores demonstrated a fair degree of methodological quality, with 69.7% for the CHEC, 73.6% for the QHES, as well as for the reporting quality, with 59.4% for CHEERS for Period 1 (74.4%, 71.5%, and 66.1%, respectively, for Period 2). An additional qualitative analysis per criterion revealed that certain items, essential for understanding the costing methodology and the results (e.g., the time horizon, discount rate, sensitivity analysis) were often only partially completed. Statistical analysis confirmed that the reviewers' scoring was consistent. The instruments identified the same top three articles, albeit with a degree of variation in the ranking. CONCLUSION: Qualitative and quantitative assessment of cost analyses in EBRT exhibits a fair level of study quality in terms of the methodology and reporting transparency. The impact of cost calculations on the final HEE result appears to be underestimated, and increased transparency of the data sources and the methodologies is needed.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Defourny N, Monten C, Grau C, et al. Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data? Radiother Oncol. 2019. PMID: 31630866. doi:10.1016/j.radonc.2019.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。